Publish in this journal
Journal Information
Share
Share
Download PDF
More article options
ePub
Visits
...
Original Article
Available online 8 December 2021
JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature
Inhibidores de receptores JAK quinasa e infección por virus varicela zoster en pacientes con artritis reumatoide. Revisión sistemática de la literatura
Visits
...
Carmen Olga Sánchez Gonzáleza,
Corresponding author
colga.sanchez@salud.madrid.org

Corresponding author.
, Juan Carlos Nieto Gonzálezb
a Sección de Reumatología, Hospital Universitario del Sureste, Arganda del Rey, Madrid, Spain
b Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Received 23 January 2021. Accepted 10 June 2021
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (5)
Table 1. Available JAK kinase inhibitors and under study in rheumatoid arthritis.
Table 2. Tofacitinib studies.
Table 3. Studies on baricitinib.
Table 4. Studies on upadacitinib and filgotinib.
Table 5. Studies on peficitinib and decernotinib.
Show moreShow less
Abstract
Objectives

JAK kinase inhibitors (JAKi) are a new therapeutic option in the treatment of rheumatoid arthritis, but they are not without risks, especially the incidence of herpes zoster (HZ).

Material and methods

Systematic literature review that evaluates the incidence of HZ published in the clinical trials of the different JAK is marketed or under study.

Results

The HZ rates ranged between 1.51 and 20.22. The results were expressed mainly as a percentage of events. The most recent studies better categorized the incidence of HZ and its severity.

Conclusion

JAK is are associated with an increased risk of HZ. Although the HZ rates of the selective JAK1 JAK is are lower, more studies are needed to confirm these results.

Keywords:
Rheumatoid arthritis
JAK inhibitors
Herpes zoster
Resumen
Objetivos

El objetivo de esta revisión sistemática es evaluar la infección por herpes zoster (HZ) publicada en los ensayos clínicos fase II y fase III de pacientes con AR en tratamiento con inhibidores de JAK (iJAK).

Material y métodos

Revisión sistemática de la literatura que evalúa la incidencia de HZ publicada en los ensatyos clínicos de los distintos iJAK comercializados o en estudio.

Resultados

Las tasas de HZ variaron entre el 1.51 y 20.22. Los resultados se expresaron principalmente en porcentaje de eventos. Los estudios más recientes categorizaron mejor la incidencia de HZ y su gravedad.

Conclusión

Los iJAK se asocian a mayor riesgo de HZ. Aunque las tasas de HZ de los iJAK sleectivos de JAK1 son menores, son necesarios más estudios que confirmen estos resultados.

Palabras clave:
Artritis reumatoide
Inhibidores de JAK
Herpes zoster

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?